Where does Mylan Laboratories Limited rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Mylan Laboratories Limited ranks #11,013 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Mylan Laboratories Limited hold?

Mylan Laboratories Limited holds 28 US utility patents granted between 2015 and 2025, spanning 11 technology areas.

What is Mylan Laboratories Limited's Innovation Score?

Mylan Laboratories Limited has an Innovation Score of 30.4 out of 100 (34th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Mylan Laboratories Limited focus on?

Mylan Laboratories Limited's top technology area is C07D (Heterocyclic Compounds) with 20 patents, ranking #448 of 3,165 assignees active in that subclass. Grants appear in 11 CPC subclasses total.

Is Mylan Laboratories Limited's patent grant rate increasing or decreasing?

Mylan Laboratories Limited's recent grant velocity is -71% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Mylan Laboratories Limited's patents?

Mylan Laboratories Limited's patents average 10.7 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Mylan Laboratories Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Mylan Laboratories Limited

USPTO PatentsView assignee record - 28 granted patents across 11 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Mylan ranks #11,013 of 49,997 tracked US assignees by granted-patent volume, with 28 patents across 11 technology areas.

#11,013
of 49,997 US assignees by volume: 34th percentile
by Innovation Score (30.4/100): 10.7
avg claims per patent: -71%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R11013 · Foreign Corporation #11,013 · 28 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-PAR · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 28 grants
UPPER-Q #11,013/49,997
PHOTO-FINISH Mersana Therapeutics
CPC-FOCUS C07D · 11 areas
INNOV-THIN 30.4/100
CLAIMS-PAR 10.7 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -71% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Mersana Therapeutics, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Mylan’s 30.4 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 11.6 pts (38%) Velocity 0.7 pts (2%) Breadth 11.7 pts (38%) Claim depth 6.4 pts (21%)

Qualcomm Incorporated · highest

85
C-Smartlink… · near

30
Daiwa Kasei Industry · near

30
Mylan Laboratories · this assignee

30
Tantalum Innovations · near

30
Ojai Retinal… · near

30
3D Lighting… · lowest

7

What this shows Mylan's Innovation Score is 30.4/100 (34th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Mylan?

Each dot is one of Mylan’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Mylan’s own 10.7 claims/patent is at or below the 16.6 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Mylan vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Mylan's grants concentrate

Mylan Laboratories Limited is a focused PatentsView assignee: 11 CPC subclasses with 71.4% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2015 (5 grants) versus a trough of 1 in 2022. By volume, Mylan sits between Mersana Therapeutics, Inc. and NEW World Medical, Inc..

Mylan's three-year grant acceleration

Mylan Laboratories Limited shows 1 grants in 2022–2024 against only 10 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Mersana Therapeut…

28
Metal Raptor

28
Mirka

28
Mux

28
Nanjing Forestry…

28
National Christma…

28
Neogen

28
NEW World Medical

28
Mylan Laboratories ◀

28

What this shows Mylan holds 28 patents at rank #11,011, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Mylan

By rank, the assignees closest to #11,011 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Mylan's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Mylan, neither rank-band nor same-CPC leaders (those blocks stay above). In C07D (Heterocyclic Compounds), Mylan ranks #448 of 3,165 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (30 here).

Daiwa Kasei Industry Co., Ltd. 30 C-Smartlink Information Technology Co., Ltd. 30 Tantalum Innovations Limited 30 Ojai Retinal Technology, LLC 30

Mylan's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

30 34th percentile higher than 34% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Mylan Laboratories Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	5	17.9%
2016	2	7.1%
2017	4	14.3%
2018	5	17.9%
2019	5	17.9%
2020	5	17.9%
2022	1	3.6%
2025partial year	1	3.6%

Which technologies does Mylan Laboratories Limited patent most?

C07D - Heterocyclic Compounds 20

C07C - Acyclic OR Carbocyclic Compounds 11

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 10

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 6

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 4

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 4

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 3

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 3

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 3

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 2

C07J - Steroids 1

Top 11 of 11 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Mylan Laboratories Limited's patent record in context - here's where to go next.

Mylan Laboratories Limited's lead technology class is C07D (Heterocyclic Compounds), 71.4% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #11,013 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Mylan Laboratories Limited against Mersana Therapeutics, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 30.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.